Physician profile
Michael Vincent Okeefe
NPI 1528159159
$1,875.16
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $257.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $320.68 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $290.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $244.81 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $199.04 | 2019-2020 | |
| Edwards Lifesciences Corporation | $149.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $145.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $118.77 | 2019 | |
| Gilead Sciences, INC. | $108.54 | 2019 | |
| Atricure, INC. | $63.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $62.80 | 2019-2020 | |
| Cardiovascular Systems INC. | $61.62 | 2019-2020 | |
| Abbott Laboratories | $57.49 | 2019-2020 | |
| Lundbeck LLC | $24.29 | 2019 | |
| Boston Scientific Corporation | $15.79 | 2019 | |
| Teleflex LLC | $12.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Okeefe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.